Antipsychotic switching in schizoaffective disorder: A systematic review

Andréa Murru; Diego Hidalgo; Miquel Bernardo; Julio Bobes; Jerónimo Sáiz-Ruiz; Cecilio Álamo; Eduard Vieta

doi:10.3109/15622975.2015.1012225

Abstract

1 min read

Antipsychotic switching in SZA is a neglected topic that would need better profiling. Clinicians should keep in mind the receptor binding characteristics of drugs in order to optimize transitions. Evidence supports the switch to aripiprazole and lurasidone, less strongly to risperidone and ziprasidone. The switch to risperidone long-acting injectable is supported, especially in patients with limited treatment adherence to oral therapy.

Related publications

Article2013

Antipsychotic switching in bipolar disorders: a systematic review

Iría Grande, Miquel Bernardo, Julio Bobes, Jerónimo Sáiz-Ruiz, Cecilio Álamo, Eduard Vieta

Article2010

Developing an Individualized Treatment Plan for Patients With Schizoaffective Disorder

Eduard Vieta

Article2005

The treatment of mixed states and the risk of switching to depression

Eduard Vieta

Article2008

A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone

Eduard Vieta, E. Nieto, Aurea Autet, Adriane Ribeiro Rosa, José Manuel Goikolea, Núria Cruz, Pere Bonet

Article2024

Influence of CYP2C19 and CYP2D6 on side effects of aripiprazole and risperidone: A systematic review

Emma Y De Brabander, Kristian Kleine Schaars, Thérèse van Amelsvoort, Monika Budde, Urs Heilbronner, Allan H. Young, Mário F. Juruena, Eduard Vieta, Natalia E. Fares‐Otero, Martien J. Kas, Markus M. Nöthen, Alexandra Philipsen, Laura L. Kilarski, Jonathan Laatsch, Moritz J. Rossner, Sven P. Wichert, Ramona Moldovan, Noam Shomron, Thomas G. Schulze, Roger Man King Ng, Nigel Olisa, Erik Van der Eycken, Teuntje A. D. Pelgrim,